Class Action Lawsuit Filed Against Pacira BioSciences: What Investors Need to Know
On February 25, 2025, Levi & Korsinsky, LLP announced the filing of a class action securities lawsuit against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX). The lawsuit alleges that Pacira and certain of its top executives violated securities laws by making false and misleading statements to the investing public.
Class Definition and Time Frame
The lawsuit seeks to recover losses on behalf of Pacira investors who purchased or otherwise acquired the Company’s securities between August 2, 2023 and August 8, 2024 (the “Class Period”).
Allegations of Securities Fraud
The complaint alleges that Pacira and its executives made materially false and misleading statements regarding the Company’s financial condition and business prospects. Specifically, the lawsuit alleges that the defendants failed to disclose: (1) that the Company was experiencing declining sales of its EXPAREL product, (2) that the Company was experiencing increased competition in the market for its products, and (3) that the Company’s financial statements were materially misstated.
Impact on Investors
As a result of these alleged false and misleading statements, Pacira’s stock traded at artificially inflated prices during the Class Period. When the truth was revealed, the Company’s stock price fell significantly, causing investors to suffer substantial losses.
Impact on the World
The filing of this class action lawsuit against Pacira BioSciences may send a strong message to other publicly traded companies to ensure the accuracy and transparency of their financial statements and disclosures. The lawsuit may also lead to increased scrutiny of the Company’s business practices and financial reporting.
Next Steps for Investors
If you invested in Pacira BioSciences securities during the Class Period, you may be entitled to recover your losses. To learn more about the class action lawsuit and your potential recovery, contact Levi & Korsinsky, LLP as soon as possible.
- Email: [email protected]
- Phone: 646-202-5711
- Website: https://cases.levikorsinsky.com/pacira-biosciences-inc-pcrx-class-action-lawsuit/
Conclusion
The filing of this class action lawsuit against Pacira BioSciences is a reminder to investors to carefully monitor the accuracy and transparency of the financial statements and disclosures of the companies in which they invest. Investors who purchased Pacira securities during the Class Period may be entitled to recover their losses. For more information, contact Levi & Korsinsky, LLP as soon as possible.
Disclaimer: Levi & Korsinsky, LLP is a nationally recognized law firm with offices in New York, Philadelphia, and Washington D.C. We have extensive expertise in prosecuting securities litigation involving financial fraud, accounting fraud, and violations of securities laws. Our attorneys have recovered hundreds of millions of dollars for aggrieved investors.
